While the drugmaker did not disclose the location of the new facility, Aurobindo expects it to be operational by 2018.
Aurobindo formed a joint venture with India-based vaccine manufacturer Tergene Biotech to develop a pneumococcal conjugate vaccine — a commercially available innoculation that has limited competition and a global market of more than $6 billion.
Through the agreement, Aurobindo will hold a majority stake in Targene and fund product development over the next three years.
“A cGMP pilot plant for clinical lot manufacture is ready and we are now working on clinical trial protocols. The plans are to create infrastructure for 50 million dosage per annum, with the first phase launch being targeted for 25 million doses. All these efforts are being synchronized to achieve commercial launch of Aurobindo’s branded products in 2018,” Aurobindo said in its annual report.
More articles on supply chain:
Supply chain tip of the week: 7 must-haves to justify innovative investments
Lethal drug poses new threat to the opioid epidemic
Study: Drug cost predictions overestimate actual healthcare spending
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
